Cognition Therapeutics (NASDAQ:CGTX) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research report report published on Wednesday morning,Benzinga reports. Chardan Capital currently has a $11.00 target price on the stock.

A number of other equities analysts have also recently issued reports on the company. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. HC Wainwright upped their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $8.30.

Cognition Therapeutics Stock Down 4.2 %

Cognition Therapeutics stock opened at $0.50 on Wednesday. The company has a 50 day moving average of $0.68 and a 200-day moving average of $0.58. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The stock has a market capitalization of $20.57 million, a PE ratio of -0.51 and a beta of 0.96.

Institutional Trading of Cognition Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Cognition Therapeutics during the fourth quarter valued at approximately $26,000. Two Sigma Investments LP raised its stake in shares of Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after purchasing an additional 42,321 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics in the 3rd quarter valued at approximately $27,000. Sigma Planning Corp boosted its holdings in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after buying an additional 28,705 shares in the last quarter. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.